First Generic Launch has Significant First-Mover Advantage Over Later Generic Drug Entrants

Jul 08 13:07 2019 Print This Article

Generic drugs perform better financially if they get to market first. The advantage is amplified if they get there more than one month ahead of competitors.

The post First Generic Launch has Significant First-Mover Advantage Over Later Generic Drug Entrants appeared first on DrugPatentWatch - Make Better Decisions.The post First Generic Launch has Significant First-Mover Advantage Over Later Generic Drug Entrants appeared first on Biotechblog.

Read More

About Article Author

Biotech Blog

  Categories:

Related Items

The Ten Best Performing Canadian Life Sciences Stocks of 2019

It was another up and down year for Canadian Life Sciences stocks. In 2018, the downfall of the sector came in the last couple of months. A year later, it happened early when cannabis stocks began to collapse. (The S&P TSX Pharma & Biotech Index lost almost half of its value between March and the [ ...

Acasti Pharma placed under review by Mackie Research Capital

Disappointing results for its lead product candidate CaPre have led Mackie research capital analyst André Uddin to place Acasti Pharma (Acasti Pharma Stock Quote, Chart, News TSXV:ACST) under review. This morning, Acasti reported topline results for Trilogy 1 Phase Three trail of CaPre that saw th ...

Tech Talk for Thursday January 9th 2020

Pre-opening Comments for Thursday January 9th U.S. equity index futures were higher this morning. S&P 500 futures were up 11 points in pre-opening trade. Index futures were virtually unchanged following release of Weekly Initial Jobless Claims at 8:30 AM EST. Consensus was unchanged from the previo ...

Acasti Pharma keeps “Top Pick” Status at Echelon for 2020

Quebec-based omega-3 drug developer Acasti Pharma (Acasti Pharma Stock Quote, Chart, News TSXV:ACST) is keeping its “Top Pick” status from Echelon Wealth Partners analyst Douglas Loe. In a research update to clients Tuesday, Loe maintained his “Speculative Buy” rating and $4.00 price target ...

Tech Talk for Monday January 6th 2020

  The Bottom Line The intermediate uptrend in world markets stalled on Friday on news of rising conflict in the Middle East.   Observations Seasonal influences this year continue to follow their historic pattern. Note seasonal charts below showing that most equity markets have a history of weake ...

Jim Cramer says this pot stock is one you should own

Cannabis therapeutics company GW Pharmaceuticals (GW Pharmaceuticals Stock Quote, Chart, News NASDAQ:GWPH) lost almost half of its value over the past six months, but the stock has been unfairly lumped into the broader cannabis selloff, an unfair predicament, according to Jim Cramer, who thinks GW ...

HLS Therapeutics gets a price target hike at Stifel Canada

Based on its strong growth profile for both sales and EBITDA, Stifel Canada analyst Justin Keywood on Tuesday raised his target price for HLS Therapeutics (HLS Therapeutics Stock Quote, Chart, News TSX:HLS). Shares of Toronto-based specialty pharma company HLS Therapeutics spiked on Tuesday as the ...

Upcoming Talk: Finding and Evaluating BioPharmaceutical Market Entry Opportunities

I’ll be giving a talk on Finding and Evaluating Market Entry Opportunities at the 13th Annual Pharma Resource Planning & Portfolio Management in Philadelphia, PA on February 6th, 2020. You can… The post Upcoming Talk: Finding and Evaluating BioPharmaceutical Market Entry Opportunities appeared ...

HLS Therapeutics has a winner in Vascepa, Stifel says

On the back of a US FDA label expansion for Vascepa, Canadian specialty pharma company HLS Therapeutics (HLS Therapeutics Stock Quote, Chart, News TSX:HLS) got a target price raise from Stifel Canada analyst Justin Keywood, who in a client update on Monday reaffirmed his “Buy” recommendation wi ...

Is Knight Therapeutics worth owning?

Specialty pharma company Knight Therapeutics (Knight Therapeutics Stock Quote, Chart, News TSX:GUD) saw its share price spike in October on news of a major acquisition, but the stock has now dropped to its previous level. What gives? It’s all part of the company’s long-term vision, says portfol ...